吉西他滨联合替吉奥治疗晚期胰腺癌的疗效分析

发布时间：2018-05-13 01:04

本文选题：晚期 + 胰腺癌　；参考：《中国医学科学院学报》2017年04期

【摘要】：目的探讨吉西他滨联合替吉奥治疗局部晚期和转移性胰腺导管腺癌的疗效和不良反应,以及可能影响患者生存的因素。方法回顾性分析北京协和医院肿瘤内科2014年1月至2017年1月病理确诊并接受吉西他滨联合替吉奥方案(第1、8天吉西他滨1000 mg/m~2静脉滴注30 min;第1~14天口服替吉奥40~60 mg/次,每日2次,每21天为1个周期)一线治疗的胰腺导管腺癌患者的临床资料,所有患者至少接受2周期化疗、有疗效评估和随访资料。结果 60例晚期胰腺癌患者纳入分析,疾病部分缓解13例(22%),稳定37例(61%),进展10例(17%),总体中位无进展生存期7个月(95%CI=6-10),中位总生存期12个月(95%CI=9-20)。单因素分析和多因素分析均显示原发灶切除对无进展生存期、肺转移对总生存期有显著影响。最常见3~4度不良反应为中性粒细胞减少(27%)、白细胞减少(18%)。结论吉西他滨联合替吉奥方案一线治疗晚期胰腺癌有效率较高,不良反应易于管理。
[Abstract]:Objective to investigate the efficacy and adverse reactions of gemcitabine combined with tegugio in the treatment of locally advanced and metastatic pancreatic ductal adenocarcinoma and the possible factors affecting the survival of the patients. Methods from January 2014 to January 2017, the pathologically confirmed patients were treated with gemcitabine combined with tegueoside (1000 mg/m~2 intravenous drip 30 minutes on the 1st day of the eighth day and the first 14 days after oral administration of tegol 4060 mg/, twice a day), methods the patients were treated with gemcitabine 1000 mg/m~2 intravenously for 30 minutes from January 2014 to January 2017 in the Department of Oncology, Peking Union Hospital. Clinical data of patients with pancreatic ductal adenocarcinoma treated every 21 days. All patients received at least 2 cycles of chemotherapy, and the results were evaluated and followed up. Results 60 patients with advanced pancreatic cancer were included in the analysis, 13 patients with partial remission of the disease, 37 patients with stability, 10 patients with progression, 10 patients with progression. The overall median survival time was 7 months. The median total survival time was 12 months. Univariate analysis and multivariate analysis showed that primary resection had a significant effect on progression free survival and lung metastasis had a significant effect on total survival. The most common adverse reactions were neutropenia, leukopenia and neutropenia. Conclusion the efficacy of gemcitabine combined with tigio regimen in the treatment of advanced pancreatic cancer is high, and the adverse reactions are easy to be managed.
【作者单位】：中国医学科学院北京协和医学院北京协和医院肿瘤内科;北京大学临床研究所生物统计部;中国医学科学院北京协和医学院北京协和医院放射科;
【分类号】：R735.9

【相似文献】